p21 Antibody / CDKN1A

Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT

Optimal dilution of the recombinant CDNK1A antibody to be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

This mAb recognizes a 21kDa protein, identified as the p21WAF1 tumor suppressor protein, expressed by the CDNK1A gene. This mAb is highly specific to CDNK1A/p21 and shows no cross-reaction with other closely related mitotic inhibitors. p21WAF1 is a specific inhibitor of cdk's and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Its expression is induced by the wild type, but not mutant, p53 suppressor protein. Normal cells generally display a rather intense nuclear p21 expression. Loss of CDNK1A expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

Recombinant full-length human protein was used as the immunogen for the recombinant CDNK1A antibody.

This recombinant CDNK1A antibody is available for research use only.

Nuclear

Protein A affinity chromatography

P38936